RU2583886C2 - Multipotent vaccine for prevention and treatment of primarily invasive and infectious diseases, method of use - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, particularly to veterinary science and medicine. Disclosed is a vaccine comprising as an antigen chitin and derivatives thereof at a concentration of 0.01-5 % per ml. Vaccine is used 1-8 times every 1-30 days. Said multipotent vaccine may be used both separately and as part of or in conjunction with other vaccines, antibiotics, antiparasitics and chemotherapeutic agents, adjuvants, immunostimulants, and for desensitisation in body allergies caused by agents containing chitin.

EFFECT: invention can be used for prevention and treatment of diseases, pathogens of which comprise chitin.

8 cl, 7 tbl, 34 ex

Description

The invention relates to biotechnology, in particular to veterinary medicine and medicine, and can be used for the prevention and treatment of diseases whose pathogens include chitin.

In order to create immunity in the prevention and treatment of infectious and invasive diseases, vaccines are used - preparations obtained from attenuated or killed pathogens (1). Immune reactions develop upon the introduction of a foreign antigen (antibody production, delayed or immediate hypersensitivity, cellular reactivity), and the vaccinated organism develops immunity to reinfection against protective antigens of the pathogen.

The need for immunization against several infections at once led to the creation of associated (multivalent) vaccines, which allows for the simultaneous formation of immunity against several diseases. Numerous associated vaccines against various pathogens are currently developed and used in practice.

For the prevention of viral diseases developed: associated vaccine against rhinotracheitis and parainfluenza viruses; pig vaccine associated vaccine.

For the prevention of bacterial diseases - DTP - adsorbed pertussis-diphtheria-tetanus vaccine; associated vaccine against emphysematous carbuncle and leptospirosis in cattle; concentrated polyvalent aluminum hydroxide vaccine against bradzot, infectious enterotoxemia, malignant edema of sheep and lambs dysentery.

For the simultaneous prophylaxis of viral and bacterial diseases, a vaccine was developed against viral diarrhea, rota- and coronavirus diseases, and calves esherichiosis; combined vaccine against infectious rhinotracheitis, parainfluenza, viral diarrhea and calf pasteurellosis; concentrated inactivated vaccine against parvovirus disease, leptospirosis, aujeszky's disease, reproductive-respiratory syndrome and swine erysipelas; vaccine against plague, adenovirus infections, parvovirus, coronavirus enteritis and leptospirosis in dogs; associated vaccine against carnivore plague, infectious hepatitis, parvovirus enteritis, parainfluenza, type 1, 2 adenovirus infection, leptospirosis and rabies; Infanrix Hexa vaccine against viral hepatitis B, diphtheria, tetanus, poliomyelitis, pertussis and hib (2, 3, 4).

The widespread use of associated vaccines indicates not only the high efficiency of such vaccination methods, but also the prospects of this area of research in the field of specific disease prevention.

However, the search and isolation of specific protective antigens is a complex scientific and practical work. Moreover, pathogens often contain protective antigens with an unstable and variable structure, which necessitates the search for less immunogenic, but more stable constant antigens. In this capacity, many researchers are trying to use some group antigens, for example, Kuna antigen in gram-negative bacteria, cross-reacting Escherichia, Klebsiella, meningococcus, brucella and Yersinia antigens or structurally similar antigens of foreign origin, for example, cattle hyaluronidase to create an anthelmintic vaccine (5).

When creating associated vaccines, the selection of antigens is of great importance due to competition of antigens, which limits the possibilities for their joint use, which affects the nomenclature of the developed and used currently associated vaccines (6, 7).

One of the most common polysaccharides in wildlife is chitin, a high-molecular linear polysaccharide consisting of N-acetyl-2-amino-2-deoxy-D-glucopyranose units (8). The unique properties of chitin and its derivatives (biocompatibility, biodegradation, sorption properties, its huge reserves (it is present in many bacteria, fungi, as well as parasites - helminths, protozoa, arthropods, but they are not present in mammals)) determine a great scientific and practical interest.

Various modifications of chitin and chitosan are used as an sorbent, adjuvant in biotechnology, in cosmetology and nutrition, in wound surgery to obtain biodegradable films and in the food industry and crop production (9).

We were unable to find information where chitosan or its derivatives would be used as an antigen in the vaccine. As a prototype, it was not possible to find an object (vaccine preparation) that could simultaneously prevent parasitic, viral and bacterial diseases.

The objective of our research was to obtain a vaccine that induces specific immune responses in the body that protect the animal from diseases whose pathogens contain chitin.

The essence of the invention lies in the fact that the vaccine uses chitin and its derivatives at a concentration of 0.01-5% in ml as an antigen. The technical result is the development of an immune response to pathogens containing chitin in their structure. The vaccine is administered 1-8-fold with an interval of 1-30 days.

The possibility of carrying out the invention with the implementation of this purpose is illustrated by the following examples.

Example 1. A vaccine containing a suspension of chitin at a concentration of 0.01% in a dose of 0.2 ml was administered to 10 guinea pigs. 10 guinea pigs control infection. After 20 days, all animals are infected with a virulent strain of the Trichophiton fungus. In the experimental group 7 guinea pigs are infected, in the control - all animals - 10 animals. The average titer of anti-chitin antibodies in ELISA in animals of the experimental group before infection was 1: 156.

Example 2. A vaccine containing gramicidin-modified chitin at a dose of 0.2 ml was administered to guinea pigs, followed by infection of animals with a virulent strain of the Trichophiton fungus. As a result, 70% of guinea pigs treated prophylactically with a suspension of modified chitin resisted infection with mycosis, in contrast to untreated animals that were infected with trichophytosis.

Example 3. A vaccine containing chitin with an attached residue of aminocaproic acid in a concentration of 0.05%, in a volume of 1.0 ml is administered four times with an interval of 1 day to 5 dogs with demodecosis. All dogs recovered after 3-4 injections. The condition of the control animals, patients with demodicosis and not subjected to treatment, worsened. The titer of anti-chitin antibodies in ELISA was 1:96.

Example 4. Similar to example 3. Only the vaccine was injected with 10 intact white mice. Another 10 mice served as infection control. After 29 days, all animals are infected with a virulent strain of Staphylococcus aureus 4D. All control animals died. Among vaccinated 6 animals remained healthy for 10 days (observation period).

Example 5. A vaccine containing linoleic acid-modified carbomethyl chitin was used to treat fascioliasis in cows. The vaccine at a concentration of 0.01% was administered to animals in a volume of 3 ml. In 20 cows, fasciose invasion was detected by ovoscopy. Three animals were treated three times, and 10 were left untreated as a control. After 40 days, helminth eggs were not found in the feces of the treated cows. In all control animals, excretion of fasciolus eggs with feces continued. The average titer of anti-chitin antibodies in ELISA was 1:68.

Example 6. Similar to example 5, but the vaccine was used to prevent anaplasmosis in cattle. 250 heads of cows were treated 3 times in the focus of anaplasmosis. Not a single animal became ill, while in the control, infection reached 26%.

Example 7. Chitin carbomethyl was modified by the addition of linoleic acid and the active substance of a multipotent vaccine was obtained. A vaccine at 1% concentration was used to treat microsporia in cats. 5 cats received 4 injections of the drug, after which they recovered. In 5 control animals, changes for the better were not observed.

Example 8. A vaccine containing chitin modified with iron ions was used to treat cattle hypodermatosis. Affected animals were 3 times injected with 5 ml of modified chitin at a concentration of 0.5%. After 40-60 days, the larvae emerging under the skin were lysed in 6 out of 10 cows. In the control animals, complete maturation and emergence of viable larvae were observed.

Example 9. Similar to example 8, but they treated echinococcosis in sheep. After the third injection, the sheep were given albendazole. It was noted that 30–40 days after the first injection, in all animals, echinococcotic vesicles began to decrease, and the pathogen died. In control animals given albendazole alone, the pathogen remained viable.

Example 10. To obtain a vaccine, chitin succinate was combined with a tetanus toxin protein. The resulting vaccine was used to prevent dirofilariasis in dogs. For this, the dogs in the kennel were divided into two groups. One group of 85 dogs was vaccinated with this vaccine, another group of dogs - 189 animals - served as a control. After a year, not one of the vaccinated dogs was affected by dirofilariasis, while in the control 26% of the dogs were infected with dirofilariasis. The average titer of anti-chitin antibodies in the blood of dogs of the experimental group in ELISA was 1: 108.

Example 11. A vaccine similar to example 10 was used to treat sarcoptosis in pigs. A vaccine of 2% concentration in a volume of 1.0 ml was administered 2 times to pigs weighing 40-60 kg. All animals were freed from sarcoptosis within a month.

Example 12. A vaccine similar to example 10 was used as part of Freund's incomplete adjuvant for the prevention of candidiasis in white mice. Freund's vaccine and adjuvant were administered to 10 white mice, and after 20 days the mice were infected with a virulent C. albicans culture. Among the vaccinees, 8 mice survived, 80%, with completely killed in the control.

Example 13. A vaccine similar to example 10 was used in conjunction with the Polivak antifungal vaccine to treat 8 dogs with microsporia. After 2 injections, all animals recovered. In the control among 10 animals, where one Polivak was used, only 3 animals recovered.

Example 14. A vaccine containing a finely divided suspension of chitin at a concentration of 0.3% at a dose of 0.5 ml was used to treat calicivirus in cats. Chitin was administered together with interferon L and levotetracycline, after 2 injections with an interval of 3-4 days, all animals recovered. The use of one interferon in 10 control cats led to the recovery of only 2 animals.

Example 15. A vaccine containing linoleic acid modified carbomethyl chitin in its composition was used at a concentration of 0.02% to desensitize 6 dogs allergic to flea bites. There were no fleas at the time of treatment. The vaccine was administered daily in increasing doses (from 0.01 to 2 ml). After 5-8 injections, the clinical manifestations of allergies (dermatitis) disappeared. In 3 control animals to which saline was used, no changes occurred.

Example 16. A vaccine containing chitin modified with gramicidin was used for the simultaneous treatment of fascioliasis and hypodermatosis found in cattle. 16 cows were injected 3 times with an interval of 5 days, 2 ml of the drug at 5% concentration. After 40 days, the larvae of the subcutaneous gadfly began to be lysed, and the fasciol eggs in the feces ceased to be detected.

Example 17. Patients with demodicosis dogs were divided into two groups. One dog was given 0.2% vaccine containing chitin, with an interval of 3 days in doses of 0.1 ml, 0.2 ml and 0.6 ml together with ivomek. To others - only ivomek. After the second injection, clinical signs of demodicosis began to pass in the dogs. Two weeks later, laboratory tests did not reveal the presence of a tick in dogs that were injected with chitin and ivomek, while at the same time in dogs that were injected with one ivomek, ticks were detected in scrapings with a noticeable improvement.

Example 18. Four dogs with a diagnosed dipyridiosis were isolated and treated against ectoparasites and treated with a vaccine containing finely divided chitin, simultaneously with the immunostimulant Polyoxidonium. Injections were performed six times with an interval of 5 days in an increasing dosage of 0.1: 0.2: 0.4: 0.6: 0.8 and 1.0 ml. Fifteen days after the last injection, the presence of mature segments or eggs of Dypylidium caninum was not detected in the feces.

Example 19. In a farm that is disadvantageous for infectious stomatitis 25, rabbits aged 15-25 days were given a vaccine containing chitin with an attached residue of aminocaproic acid. The vaccine was administered at a concentration of 1.0% twice with an interval of 15 days at a dose of 0.1 and 0.5 ml. Another group of rabbits (15 animals) of a similar age remained untreated. By the age of four months, only one rabbit had been ill with stomatitis from the experimental group; in the control group, 12 animals fell ill, and 4 were fatal.

Example 20. Cows infected with fascioliasis (the diagnosis was established by the method of Demidov), was divided into eight groups. In one group of cows, a vaccine based on deacetylated chitin (80 kDa chitosan) in different concentrations in a volume of 1 and 5 ml was administered twice with an interval of 6 days. The seventh group - a vaccine simultaneously with the drug Politrem. The eighth group of animals served as a control; it was not subjected to treatment. Two months after the treatment, caprological studies of feces were carried out in all cows. The results are presented in table 1.

Table 1 Group number Animal species Number of animals Chitosan concentration Vaccine schedule Remained invaded (goal) one Cows twenty 0.1% 1 and 5 ml, interval of 6 days 2 2 Cows twenty 0.2% 3 3 Cows twenty 0.5% 0 four Cows twenty one% one 5 Cows twenty 3% four 6 Cows twenty 5% 2 7 Cows thirty 0.2 + Politrem 0 8 Cows 27 The control 27

Example 21. To the cows two weeks before the pasture, a vaccine was introduced into the swampy pasture areas, the active substance of which was chitosan, modified by palmetoyl chloride with a molecular weight of 500 kDa, in different concentrations. In group 5, the Dostim immunostimulant was simultaneously administered, in group 6, the antiparasitic drug Alben was simultaneously administered. All preparations were administered intramuscularly twice with an interval of 30 times in a dose of 1 and 5 ml. During the summer, the seventh group was not subjected to any anthelmintic treatments. At the end of the grazing season, the animals were examined for the presence of fasciolus eggs. An enzyme-linked immunosorbent assay a month after vaccination, the titer of antichitin antibodies in the blood of animals from group 1 was 1:69, in group 5 - 1: 121. The results are presented in table 2.

table 2 Group number Animal species Number of animals Chitosan in concentration Vaccine schedule Remained invaded (goal) one Cows 17 0.1% 1 and 5 ml, interval 30 days 2 2 Cows fifteen 5% one 3 Cows twenty 1,0% 0 four Cows eighteen 2.0% 0 5 Cows 13 0.1 + Get 0 6 Cows twenty 0.1 + Alben 0 7 Cows 22 Not processed 22

Example 22. Dysfunctional dictation of a herd of cows was divided into 5 groups according to the principle of analogues. The animals of the corresponding groups were once administered a parenteral vaccine based on chitosan with a molecular weight of 10 kDa modified with palmetoyl chloride once at a dose of 3 ml, and phenbendazole was orally administered to the third group along with the vaccine. Only four fenbendazole (Panacur) was given at the rate of 10 mg / kg live weight with control food group four.

Control group number five was not subjected to antiparasitic treatments. A month later, they carried out caprological studies. The results are presented in table 3.

Table 3 Group number Animal species Number of animals Chitosan in concentration Vaccine schedule Remained invaded (goal) one Cows 10 0.5% 3 ml one 2 Cows 10 5% 0 3 Cows 10 0.5% + Fenbendazole 0 four Cows 10 Fenbendazole one 5 Cows 10 Control animals were not treated with chemotherapeutic drugs. 9

Example 23. Helminth-free piglets at the age of one month were vaccinated with a 400 kDa chitosan-based multipotent vaccine (group 1 and 3) and a chitin-based vaccine (group 2 and 4). The vaccine was administered twice in doses of 0.2 and 0.4 ml. Group No. 5 was not subjected to preventive vaccination. All groups of animals were not treated with anthelmintic drugs for 9 months. Nine months after this, a Fulleborn feces study was carried out. Ascaris eggs were not found in 88-92% of piglets treated with chitosan vaccine, 60-72% of piglets immunized with chitin vaccine resisted ascariasis. Ascaridosis was observed in 84% of control piglets that were not treated and kept together with the treated. The results are presented in table 4.

Table 4 Group number Animal species Number of animals Chitosan in concentration Vaccine schedule % invasive animals one Piglets 25 2.0% 0.2 and 0.4 ml, interval 30 days 8 2 Piglets 25 2.0% 28 3 Piglets 25 1,0% 12 four Piglets 25 1,0% 40 7 Piglets 25 Not processed 76

Example 24. Piglets against ascariasis were introduced a vaccine, which included chitosan and chitin. The animals of the first group received the vaccine three times in doses of 0.2: 0.4: 0.6 ml. The second group - once in a dose of 0.3 ml. Gilts from the third group were fed adipate piperazine at a dose of 12 g per animal. The results are presented in table 5.

Table 5 Group number Animal species Number of animals Chitosan and Chitin Concentration Application chart % invasive animals one Piglets fifty 0.2% + 0.2% 0.2, 0.4, 0.6 ml, interval 15 days 8 2 Piglets fifty 0.1% + 0.2% 0.3 ml fourteen 3 Piglets fifty Adipate piperazine 0 four Piglets fifty Not processed one hundred

Example 25. Nine puppies with toxocariasis were injected three times in doses of 0.2: 0.4: 0.8 ml with an interval of 1 day, containing a 0.2% solution of chitin with a molecular weight of 100 kDa modified with hexomethylenediamine. Within a month, the clinical manifestations of the disease were monitored and, after this period, the Fulleborn method conducted a study of dog excrement. Coprological studies of Tohosa canis eggs in puppies treated with the preparation were not detected.

Example 26. Eight mongrel dogs were given a two-time vaccine based on chitosan with a molecular weight of 25 kDa together with the Polyoxidonium immunostimulant in doses of 0.5 and 1 ml. A month later, these and control dogs were fed the internal organs of sheep affected by larval echinococcosis. After three months, a diagnostic deworming of all dogs was carried out and the presence of isolated segments of helminths and eggs of Dypylidium caninum was determined in the selected feces. The results are presented in table 6.

Table 6 No. p.p. Example No. Number of animals Chitosan concentration and drug Application chart Number of infested one 26 8 5% + Polyoxidonium 0.5 and 1.0 ml 0 2 26 four The control four 3 27 four one% 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 ml 0 four 27 5 0.2% 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 ml one 5 27 5 0.2% 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 ml 0 6 27 9 Ivomek 3

Example 27. Twenty-three dogs diagnosed with demodicosis were treated. The first group of 4 dogs was given a vaccine based on chitosan with a molecular weight of 500 kDa modified with copper ions, the second group of 5 dogs was given a vaccine based on chitosan modified with linoleic acid, the third group was given chitosan and the antibiotic amoxicillin. Chitosan-based vaccines at a concentration of 0.2% were administered six times in doses of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 ml with an interval of three days. In all dogs, after the third injection of a chitosan-based drug, itching decreased, skin scaly began to disappear, and hairline began to recover. A control group of dogs with demodecosis, in the amount of nine goals, was treated with ivomecom. Ivomek was administered subcutaneously twice at a dose of 200 mg / kg of dog weight. After the end of treatment, a laboratory analysis of scrapings from the skin of treated dogs was performed, the tests gave a negative result among animals that were injected with chitosan and its modifications. Three dogs treated with ivomecom found ticks in scrapings. The results of treatment of dogs for demodicosis are presented in table 6.

Example 28. Four clinically healthy dogs were twice injected with a vaccine containing a 0.5% solution of chitosan with a molecular weight of 80 kDa, modified with gramicidin, at a dose of 0.2 and 0.5 ml. Dogs were placed in an aviary, where they contained three healthy dogs and two dogs with clinical signs of demodicosis, confirmed by laboratory tests. Together, the dogs were kept for a month, after which sick dogs were dropped off and they received a course of treatment against demodicosis. The remaining dogs were monitored for a month. As a result, in the experimental group, none of the four dogs showed signs of demodicosis, while the control, non-immunized dogs showed signs of demodicosis, which was confirmed by laboratory studies.

Example 29. Ten dogs with demodecosis were given a vaccine containing 1% solution of chitosan with a molecular weight of 20 kDa, modified with iron ions, with an interval of 3 days in doses of 0.1 ml, 0.2 ml. At the same time, the dogs were treated with Amit. After the second injection, the clinical signs of demodicosis in dogs began to disappear. Two weeks later, laboratory tests did not reveal the presence of a tick in these dogs.

Example 30. In order to prevent hypodermatosis in two groups of cattle, twice at a dose of 4 ml, with an interval of one month, an intramuscular vaccine based on chitosan with a molecular weight of 100 kDa was administered. The third group of animals was not treated and left as a control. During the year, animals were monitored. The following spring, the animals were examined by palpation for the presence of seals in the skin and the formation of fistulous capsules. Among cattle treated with the claimed drug, there were no signs of hypodermatosis. 40% of untreated animals showed clinical signs of hypodermatosis. The results in table 7.

Table 7. No. of group Example No. Animal species Number of animals Chitosan concentration and drug Application chart Number of infested one thirty Cows 31 0.1% 4.0 and 4.0 ml interval 30 days 2 2 thirty Cows 46 2% 0 3 Control 30 Cows 25 - 12 four 31 Cows twenty 5% 2, 4, 8, 10 ml interval of 5 days 2 5 31 Cows 35 5% + ribotan 0 6 31 Cows 22 5% + ivermek 0 7 31 Cows eighteen 5% + aluminum hydroxide 0

Example 31. Cattle affected by hypodermatosis were treated with a vaccine containing chitosan with a molecular weight of 20 kDa. The vaccine was used both separately and in conjunction with the Ribotan immunostimulant, the anti-parasitic drug Ivermek, and aluminum hydroxide. The drug was administered four times with an interval of five days in an increasing dosage of 2, 4, 8, 10 ml. The treatment results are presented in table 7.

Example 32. 35 rabbits with clinical signs of myxomatosis were treated with a vaccine containing 1% solution of chitosan with a molecular weight of 100 kDa, simultaneously with the Dostim immunostimulator. The vaccine was administered intramuscularly 5 times with an interval of 3 days in an increasing dosage of 0.2, 0.5 and 1.0 ml. After the second injection, the temperature returned to normal, appetite returned to normal, swelling of the eyelids and blepharoconjunctivitis went away, purulent discharge from the eyes stopped. Nodular formations in the muzzle area decreased. By the fifth injection, the condition of the rabbits returned to normal, while at the same time 5 rabbits, separated from the main group and not being treated by this time, died.

Example 33. In a farm unsuccessful for infectious stomatitis, 10 rabbits at the age of 18 days were treated with a vaccine containing chitosan in 2% concentration, modified palmetoyl chloride with a molecular weight of 80 kDa. The vaccine was administered three times with an interval of 5 days at a dose of 0.1 and 0.2 and 0.5 ml. Another nest of rabbits (7 goals) remained untreated. During the three months of follow-up, no disease was found among the rabbits of the experimental group, while 5 animals were ill with infectious stomatitis among the animals of the control group.

Example 34. In vivarium, 76 rats showed bacterial pneumonia. 60 rats were treated with a 50 kDa chitosan vaccine. The drug was administered three times in doses of 0.05, 0.1, 0.2 ml with an interval of 2 days. After treatment, rats returned to normal breathing and behavioral reflexes. At the same time, among the untreated animals, the clinical manifestation of the disease and the death of two animals continued.

Thus, the use of chitin and its derivatives as the active substance of the vaccine - antigen, allows to obtain a drug with multipotent properties, which can be used for the prevention and treatment of infectious and invasive diseases, the causative agents of which contain chitin in their structure, and the vaccine can be used immediately against several diseases, the causative agents of which belong to different taxonomic groups.

As follows from the above examples, a multipotent vaccine with a positive effect was used for the prevention and treatment of microsporia, demodicosis, staphylococcosis, fascioliasis, anaplasmosis, hypodermatosis, echinococcosis, dirofilariasis, sarcoptosis, candidiasis, calicivirosis, mycosis, stomatocariosis, mycosis, stomatocarciosis, mycosis, stomatocarciosis, and mycosis.

This multipotent vaccine can be used either alone or as part of or in combination with other vaccines, antibiotics, antiparasitic and chemotherapeutic agents, adjuvants, immunostimulants and hyperimmune serums, as well as for desensitization of the body for allergies caused by agents containing chitin.

Multipotent vaccine was tested with a positive result during 2000-2012. on laboratory animals, sheep, pigs, cattle, dogs, cats in farms and veterinary clinics of the Kaliningrad, Moscow, Volgograd and Nizhny Novgorod regions.

This invention can find wide application not only for the prevention and treatment of parasitic diseases in domestic and farm animals, but also for various diseases, the causative agents of which in their structure contain chitin.

Information sources

1. Medunitsin N.V. Vaccinology, 2004. Triad H.

2. Biological veterinary drugs in Russia: vaccines, serums, diagnosticums. Kazan. Ruthen, 2005, pp. 6-317.

3. Antigenic and immunogenic properties of the inactivated associated vaccine against pasteurellosis, salmonellosis and actinobacillus pleuropneumonia in pigs. The dissertation for the degree of candidate of veterinary sciences. Zverkov D.A. 2000, Moscow, 120 p.

4. Gulyukin M.I., Fedorov S.A. et al. Analysis of the inventive and patent-licensing activities of the VIEV, Moscow, Belgorod, Polyterra, 2013, p. 58-59.

5. RF patent 2095082, A61K 039/00, 1996. Vaccine against animal helminthiases.

6. Makarov V., Gusev A., Guseva E., Sukharev O. Fundamentals of infectious immunology. Vladimir-Moscow, “Tome”, 2000, pp. 125-126.

7. Kadymov R.A., Safarov Yu.B. Associated and complex vaccination of animals. M .: Kolos, 1974, pp. 233-242.

8. Chitin and chitosan. Receiving. Properties and application. M .: "Science", 2002, p. 10.

9. Current prospects in the study of chitin and chitosan. M.: VNIRO, 2003, pp. 131-279.

Claims (8)

1. A multipotent vaccine for the prevention and treatment of diseases whose pathogens include chitin, including a physiological solvent and antigen, characterized in that chitin and its derivatives are used as antigen at a concentration of 0.01-5% per ml. 2. A multipotent vaccine according to claim 1, characterized in that the chitosan molecules are additionally chemically modified. 3. The method of application of the multipotent vaccine according to paragraphs. 1 and 2, including 1-8-fold parenteral administration of the vaccine with an interval of 1-30 days, characterized in that it is used for the prevention and treatment of diseases whose pathogens include chitin. 4. The method according to p. 3, characterized in that the multipotent vaccine is used to treat and prevent several diseases at once, which may belong to different taxonomic groups. 5. The method according to p. 3, characterized in that the multipotent vaccine can be used in combination or in association with other vaccines. 6. The method according to p. 3, characterized in that the multipotent vaccine can be used in conjunction with antibiotics, antiparasitic and other chemotherapeutic agents. 7. The method according to p. 3, characterized in that the multipotent vaccine is used in conjunction with adjuvants, immunostimulants. 8. The method according to p. 3, characterized in that the multipotent vaccine is used to desensitize the body for allergies caused by agents containing chitin.